Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOCLEAR L.A.-130 vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of asthma (FDA-approved),Treatment of chronic obstructive pulmonary disease (COPD) (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
130 mg orally every 12 hours; extended-release tablet.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4 (major); also N-demethylation and oxidation. Exhibits non-linear pharmacokinetics.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40% bound to plasma proteins, primarily albumin. Binding is reversible and independent of concentration within therapeutic range.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Vd of 0.3-0.7 L/kg (average 0.5 L/kg) approximates total body water. This indicates extensive distribution into tissues, with higher concentrations in tissues than plasma.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral bioavailability of the sustained-release formulation approaches 100% due to complete absorption. However, food can affect absorption rate; with Theoclear L. A.-130, high-fat meals may increase peak concentration and rate of absorption.
Oral: 40-50%; Inhalation: 20-30%
No specific adjustment required; monitor serum concentrations and adjust dose based on clinical response and trough levels.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not recommended for children under 6 years; for children 6-12 years: 130 mg once daily initially, titrate based on weight and serum levels (target 5-15 mcg/m L).
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Initiate at lower end of dosing range (130 mg once daily) and titrate slowly; monitor for toxicity due to reduced clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Risk of seizures and arrhythmias at high serum levels (therapeutic range 10-20 mcg/m L),Monitor serum theophylline levels regularly,Use caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders,May exacerbate arrhythmias; ECG monitoring recommended,Drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin)
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component,Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias),Uncontrolled seizure disorder,Active peptic ulcer disease
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid high-fat meals which may alter absorption of sustained-release tablets. Limit caffeine intake from coffee, tea, cola, and chocolate. Charcoal-grilled foods may increase clearance. No specific dietary restrictions beyond caffeine moderation; maintain consistent diet to avoid fluctuations in drug levels.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (THEOCLEAR L. A.-130) is not associated with major teratogenic effects in humans. First trimester exposure does not increase risk of congenital malformations above baseline. Third trimester use may cause neonatal irritability, tachycardia, and vomiting due to transplacental transfer. Risk of fetal respiratory depression is low at therapeutic maternal levels.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose. Adverse effects in nursing infants (irritability, sleep disturbance) have been reported. Caution advised; monitor infant for toxicity.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy decreases theophylline clearance (especially third trimester due to decreased hepatic metabolism) and increases volume of distribution. Dose requirements may decrease by 20-30% in later pregnancy. Monitor serum levels and adjust dose to maintain therapeutic range (5-15 mcg/m L). Postpartum clearance returns rapidly (within 2 weeks); dose reduction may be needed to avoid toxicity.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theophylline has a narrow therapeutic index (10-20 mcg/m L). Levels >20 mcg/m L increase toxicity risk. Immunoassay cross-reactivity with caffeine and other xanthines may falsely elevate levels. Adjust dose in heart failure, liver disease, and for drug interactions with cimetidine, fluoroquinolones, and macrolides. Smoking induces metabolism requiring dose increase. Sustained-release formulations should not be crushed or chewed.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Do not crush or chew sustained-release tablets; swallow whole.,Take exactly as prescribed; do not double doses if missed.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.,Inform all healthcare providers you are taking this medication.,Do not stop suddenly without consulting your doctor.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOCLEAR L.A.-130 vs AEROLATE III, answered by our medical review team.
THEOCLEAR L.A.-130 is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOCLEAR L.A.-130 and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOCLEAR L.A.-130 is: 130 mg orally every 12 hours; extended-release tablet.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOCLEAR L.A.-130 and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOCLEAR L.A.-130 is classified as Category C. Theophylline (THEOCLEAR L.A.-130) is not associated with major teratogenic effects in humans. First trimester exposure does not increase risk of congenital malformations above base. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.